Vectura Group PLC (VEC) Given Buy Rating at Shore Capital
Vectura Group PLC (LON:VEC)‘s stock had its “buy” rating restated by Shore Capital in a research report issued to clients and investors on Wednesday.
Several other equities research analysts have also issued reports on the company. Royal Bank Of Canada lowered Vectura Group PLC to an “underperform” rating in a report on Tuesday, April 25th. N+1 Singer lowered Vectura Group PLC to a “sell” rating in a report on Monday, April 24th. Numis Securities Ltd reiterated a “buy” rating and set a GBX 225 ($2.92) price target on shares of Vectura Group PLC in a report on Friday, May 5th. J P Morgan Chase & Co reduced their price target on Vectura Group PLC from GBX 240 ($3.12) to GBX 210 ($2.73) and set an “overweight” rating for the company in a report on Friday, May 12th. Finally, Peel Hunt reiterated a “hold” rating and set a GBX 160 ($2.08) price target on shares of Vectura Group PLC in a report on Thursday, June 29th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. Vectura Group PLC has a consensus rating of “Buy” and an average price target of GBX 210.13 ($2.73).
Shares of Vectura Group PLC (VEC) opened at 113.90 on Wednesday. Vectura Group PLC has a 52-week low of GBX 109.50 and a 52-week high of GBX 166.97. The company’s 50-day moving average is GBX 112.89 and its 200-day moving average is GBX 131.35. The firm’s market cap is GBX 771.85 million.
TRADEMARK VIOLATION WARNING: “Vectura Group PLC (VEC) Given Buy Rating at Shore Capital” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.watchlistnews.com/vectura-group-plc-vec-given-buy-rating-at-shore-capital/1493015.html.
About Vectura Group PLC
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.